Collection 2 (Sep 2021 - Aug 2022) Articles

Articles
National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk
Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki
Journal:
J Clin Lipidol

First published: November 2, 2021 DOI: 10.1016/j.jacl.2019.10.014
View
- Share
Articles
Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit
Orringer CE, Blaha MJ, Stone NJ
Journal:
J Clin Lipidol

First published: November 1, 2021 DOI: 10.1016/j.jacl.2021.09.052
View
- Share
Articles
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Majithia A, Bhatt DL, Friedman AN, et al.
Journal:
Circulation

First published: October 28, 2021 DOI: 10.1161/CIRCULATIONAHA.121.055560
View
- Share
Articles
Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Verma S, Bhatt DL, Steg PG, et al.
Journal:
Circulation

First published: October 28, 2021 DOI: 10.1161/CIRCULATIONAHA.121.056290
View
- Share
Articles
European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology
Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.
Journal:
Eur J Prev Cardiol

First published: October 23, 2021 DOI: 10.1093/eurjpc/zwab160
View
- Share
Articles
Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.
Journal:
Pharmacotherapy

First published: October 17, 2021 DOI: 10.1002/phar.2635
View
- Share
Articles
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.
Journal:
Arteriosclerosis, Thrombosis, and Vascular Biology

First published: October 14, 2021 DOI: 10.1161/ATV.0000000000000147
View
- Share
Articles
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.
Journal:
Journal of the American College of Cardiology Volume 78, Issue 15, 12 October 2021, Pages 1499-1507

First published: October 12, 2021 DOI: 10.1016/j.jacc.2021.08.011
View
- Share
Articles
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.
Journal:
European Heart Journal

First published: October 12, 2021 DOI: 10.1093/eurheartj/ehab718
View
- Share
Articles
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Journal:
J Am Coll Cardiol

First published: October 12, 2021 DOI: 10.1016/j.jacc.2021.08.009
View
- Share
Articles
Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data
Kwon O, Na W, Hur J, et al.
Journal:
Cardiovasc Drugs Ther

First published: October 8, 2021 DOI: 10.1007/s10557-021-07255-2
View
- Share
Articles
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
Ambrosy AP, Yang J, Sung SH, et al.
Journal:
J Am Heart Assoc

First published: October 8, 2021 DOI: 10.1161/JAHA.120.020377
View
- Share

1 … 10 11 12 13 14

Collection 2 (Sep 2021 - Aug 2022) Articles

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Articles

Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit

Orringer CE, Blaha MJ, Stone NJ

Articles

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Majithia A, Bhatt DL, Friedman AN, et al.

Articles

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG

Verma S, Bhatt DL, Steg PG, et al.

Articles

European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.

Articles

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.

Articles

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.

Articles

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT

Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.

Articles

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.

Articles

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.

Articles

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data

Kwon O, Na W, Hur J, et al.

Articles

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

Ambrosy AP, Yang J, Sung SH, et al.

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Share

Articles

Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit

Orringer CE, Blaha MJ, Stone NJ

Share

Articles

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Majithia A, Bhatt DL, Friedman AN, et al.

Share

Articles

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG

Verma S, Bhatt DL, Steg PG, et al.

Share

Articles

European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Suleman Aktaa, Baris Gencer, Elena Arbelo, et al.

Share

Articles

Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD

Azita H Talasaz, Ai-Chen Jane Ho, Fawzia Bhatty, et al.

Share

Articles

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, et al.

Share

Articles

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT

Kazuma Oyama, Robert P Giugliano, Michael A Blazing et al.

Share

Articles

Combination lipid-lowering therapy as first-line strategy in very high-risk patients

Kausik K Ray, Laurens F Reeskamp, Ulrich Laufs, et al.

Share

Articles

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Prakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.

Share

Articles

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data

Kwon O, Na W, Hur J, et al.

Share

Articles

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

Ambrosy AP, Yang J, Sung SH, et al.

Share